checkAd

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nachrichtenquelle: Business Wire (engl.)
05.02.2021, 22:05  |  158   |   |   

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 10,250 shares of the company’s common stock to a new employee as an inducement award under the company’s 2019 Inducement Plan. In addition, the company granted a non-statutory stock option for the purchase of up to 130,000 shares to the company’s new Chief Medical Officer, Diana M. Escolar, M.D., FAAN. Both grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted as inducements material to the new employees’ acceptance of employment with the company and were approved by the Compensation Committee of the company’s Board of Directors. The stock options were granted on Feb. 1, 2021, with an exercise price of $14.55 per share, representing the closing price of AVROBIO’s common stock as reported by Nasdaq on the grant date.

The stock option awards have a 10-year term and vest over four years, with 25 percent of the original number of shares vesting on the first anniversary of the employees’ new hire date and the remainder vesting in equal monthly installments over the following three years. Vesting of the option awards is subject to continued service with AVROBIO by the employee through the applicable vesting dates.

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry leading plato gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Seite 1 von 3
AVROBIO Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 10,250 …

Nachrichten des Autors

Titel
Titel
Titel
Titel